



## Organovo Announces Release Date for Fiscal Fourth-Quarter 2016 Financial Results

May 23, 2016

SAN DIEGO, May 23, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) ("Organovo"), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, will host a conference call on Thursday, June 9, 2016 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal fourth-quarter 2016 financial results. In advance of the call on June 9, 2016, Organovo will issue its fiscal fourth-quarter 2016 earnings press release, which will be available at <http://www.organovo.com>. To participate in the teleconference, callers can dial the following numbers:

1-888-317-6003 (toll-free, U.S. callers only)

1-412-317-6061 (from outside the U.S.)

Conference Call ID: 2570234

To help ensure the conference call begins in a timely manner, please dial in five minutes prior to the scheduled start time. The conference call will also be simultaneously webcast at <http://www.organovo.com>.

For those unable to participate in the live call, a replay of the call will be available toll-free until June 16, 2016 at 1-877-344-7529 (U.S. callers only) or at 1-412-317-0088 (callers outside the U.S.). The passcode for the replay is: 2570234. An archived replay of the webcast will also be available at <http://www.organovo.com>.

### About Organovo Holdings Inc.

Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company recently launched its initial product of the planned exVive3D™ portfolio offering, the exVive3D Human Liver Tissue for use in toxicology and other preclinical drug testing. Additional products are in development, with the anticipated release of the exVive3D Human Kidney Tissue scheduled for the fourth quarter of calendar year 2016. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. Learn more at [www.organovo.com](http://www.organovo.com).

### Investor Contact:

Steve Kunszabo  
Organovo Holdings, Inc.  
+1 (858) 224-1092  
[skunszabo@organovo.com](mailto:skunszabo@organovo.com)

### Press Contact:

Jessica Yingling  
Little Dog Communications  
+1 (858) 480-2411  
[jessica@litldog.com](mailto:jessica@litldog.com)



Organovo, Inc.